Your browser doesn't support javascript.
loading
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.
Cleary, James M; Raghavan, Srivatsan; Wu, Qibiao; Li, Yvonne Y; Spurr, Liam F; Gupta, Hersh V; Rubinson, Douglas A; Fetter, Isobel J; Hornick, Jason L; Nowak, Jonathan A; Siravegna, Giulia; Goyal, Lipika; Shi, Lei; Brais, Lauren K; Loftus, Maureen; Shinagare, Atul B; Abrams, Thomas A; Clancy, Thomas E; Wang, Jiping; Patel, Anuj K; Brichory, Franck; Vaslin Chessex, Anne; Sullivan, Ryan J; Keller, Rachel B; Denning, Sarah; Hill, Emma R; Shapiro, Geoffrey I; Pokorska-Bocci, Anna; Zanna, Claudio; Ng, Kimmie; Schrag, Deborah; Jänne, Pasi A; Hahn, William C; Cherniack, Andrew D; Corcoran, Ryan B; Meyerson, Matthew; Daina, Antoine; Zoete, Vincent; Bardeesy, Nabeel; Wolpin, Brian M.
Afiliação
  • Cleary JM; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Raghavan S; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Wu Q; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Li YY; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Spurr LF; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Gupta HV; Eli and Edythe L Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Rubinson DA; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Fetter IJ; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hornick JL; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Nowak JA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Siravegna G; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Goyal L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Shi L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Brais LK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Loftus M; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Shinagare AB; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Abrams TA; Dana-Farber Brigham and Women's Cancer Center, Department of Radiology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Clancy TE; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Wang J; Dana-Farber Brigham and Women's Cancer Center, Department of Surgical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Patel AK; Dana-Farber Brigham and Women's Cancer Center, Department of Surgical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Brichory F; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Vaslin Chessex A; Debiopharm International SA, Lausanne, Switzerland.
  • Sullivan RJ; Debiopharm International SA, Lausanne, Switzerland.
  • Keller RB; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Denning S; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hill ER; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Shapiro GI; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Pokorska-Bocci A; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Zanna C; Debiopharm International SA, Lausanne, Switzerland.
  • Ng K; Debiopharm International SA, Lausanne, Switzerland.
  • Schrag D; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Jänne PA; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hahn WC; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Cherniack AD; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Corcoran RB; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Meyerson M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Daina A; Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Zoete V; SIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.
  • Bardeesy N; SIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.
  • Wolpin BM; University of Lausanne, Department of Fundamental Oncology, Ludwig Lausanne Branch, Lausanne, Switzerland.
Cancer Discov ; 11(10): 2488-2505, 2021 10.
Article em En | MEDLINE | ID: mdl-33926920
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Inibidores de Proteínas Quinases / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Inibidores de Proteínas Quinases / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article